Established in 2015 | Pioneering a New Era in Regenerative Medicine

U-NEURON Biomedical is an innovative biotechnology company dedicated to regenerative medicine and exosome applications. Centered on proprietary amniotic fluid stem cell (AFSC) technology, combined with exosome development and functional biologics, U-NEURON has built a comprehensive business layout spanning therapeutics, cosmeceuticals, and health supplements. The company is committed to establishing a world-leading Exosome Design House × Foundry business model, accelerating the transition of regenerative medicine from laboratory to market through integrated design, manufacturing, and application.

 
About Us - 永立榮生醫
About Us - 永立榮生醫
Global patent portfolio: stem cell and exosome applications
Number Patent technology title Patent numbers and status in various countries
01 Pharmaceutical compositions containing amniotic fluid stem cell spheroids and uses thereof in treating urinary incontinence ߇鰟缠TW: I751692 B (Granted) ߇갟縠US: 11766460 B2 (Granted) ߇谟糠CN: 202010951931.5 (App)
02 Treatment of erectile dysfunction using amniotic fluid mesenchymal stem cells ߇갟縠US: 18/1873344 (App) / ߇鰟缠TW: 112110504 (App) / ߇氟纠AU: 2023240916 (App) ߇谟禠CA: 3254662 (App) / ߇갟纠EPC: 23773862.0 (App) / ߇ﰟ絠JP: 2024-555918 (App) ߇ట締KR: 10-2024-7031222 (App) / ߇Ⱏ羠MY: PI2024005419 (App) / ߇谟糠CN: 202380028465.5 (App)
03 Uses of amniotic fluid cell secretome in treating dry eye disease ߇鰟缠TW: I856252 B (Granted) / ߇谟糠CN: 202210014790.3 (Granted) / ߇갟纠EPC: EP 4098270 B2 (Granted) ߇ﰟ絠JP: 7580130 B2 (Granted) / ߇ట締KR: 10-2794579 B1 (Granted) / ߇氟纠AU: 2022203692 (Granted) ߇갟縠US: 18/772,790 (App)
04 Compositions containing amniotic fluid stem cells or derivatives thereof and methods of use ߇鰟缠TW: I867713 B (Granted) / ߇谟笠SG: 11202501260U (App) ߇갟縠US: 19/106,218 (App) / ߇谟糠CN: 202380061896.1 (App) ߇갟纠EPC: 23782731.6 (App) / ߇Ⱏ羠MY: PI2024005419 (App)
05 Freeze-dried stem cell powder derived from Cervidae, preparation method, uses, and compositions thereof ߇鰟缠TW: M667337 (Utility Model Granted) / ߇鰟缠TW: 113142143 (App) ߇갟縠US: 19/378289 (App) / ߇Ⱏ羠MY: I2025006851 (App)
06 Mixed conditioned medium or exosome compositions derived from Cervidae stem cells of different origins, preparation methods, and uses thereof ߇갟縠US: 63/994,036 (Provisional App)
07 Method for producing function-enhanced exosomes using low-concentration resveratrol derivative (Piceatannol) ߇갟縠US: 63/994,110 (Provisional App)
1

%

of the team members hold a master’s degree or higher, including five PhD-level researchers.

 
1

senior technical professionals with an average of over 14 years of industry experience.

 

Our Business

U-NEURON Biomedical drives long-term corporate expansion through a Dual-Engine Growth Model. On one hand, through drug development, we continuously accumulate high-value patents and core technologies, focusing on UA002 and UB003 stem cell/exosome drug candidates to capture high-barrier, high-growth therapeutic markets. On the other hand, through the i-ExoCraft® Exosome Design House, we rapidly translate R&D achievements into skincare, dietary supplements, pet care, and other diverse sectors, accelerating commercialization and market expansion.

With R&D as the core and commercialization as the extension, the two engines create a parallel development model of technology-driven innovation and revenue growth, building a sustainable and scalable biomedical platform.

About Us - 永立榮生醫

Market Strategy

Pioneering Regenerative Medicine: A New Era of Amniotic Fluid Cells and Exosomes